Phase 1 Single and Multiple Dose Clinical Trials (ASCENT‐1 and ASCENT‐2) for Dose‐Finding of PRX012 in Participants with Biologically Confirmed Alzheimer’s Disease

Chad Swanson, Ferenc Martényi, Ryan E Tooker, Brian M Campbell, Ann Johnson, Lingnan Li, Mary E Quiceno, Wagner M Zago, Gene G Kinney, Hideki Garren · 2025

Read Phase 1 Single and Multiple Dose Clinical Trials (ASCENT‐1 and ASCENT‐2) for Dose‐Finding of PRX012 in Participants with Biologically Confirmed Alzheimer’s Disease by Chad Swanson, Ferenc Martényi, Ryan E Tooker, Brian M Campbell, Ann Johnson, Lingnan Li, Mary E Quiceno, Wagner M Zago, Gene G Kinney, Hideki Garren (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11713914.txt.

Description

Chad Swanson and nine co-authors lay out two early drug trials that seek the right dose of a new Alzheimer's drug, in a 2025 conference paper. The drug, PRX012, is an antibody that clears harmful forms of amyloid from the brain. It is given as a shot under the skin. New drugs of this class have already slowed decline in some patients.

The first trial gives a single shot to healthy adults and to patients whose disease is confirmed by scan, with doses rising step by step. The second gives repeat doses to patients and adds checks on how the drug acts in the body. Both trials track safety, body response, and how long the drug lasts. The work will set the dose for larger tests of whether the drug helps.

Catalog record

CREATORChad Swanson, Ferenc Martényi, Ryan E Tooker, Brian M Campbell, Ann Johnson, Lingnan Li, Mary E Quiceno, Wagner M Zago, Gene G Kinney, Hideki Garren
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE3 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11713914

Browse the full library · About the Tower of Babel